Cargando…

BuShenKangShuai Tablet Alleviates Hepatic Steatosis via Improving Liver Adiponectin Resistance in ApoE(−/−) Mice

BuShenKangShuai tablet (BSKS) is a Chinese herbal compound, which has been used to treat nonalcoholic fatty liver disease and cardiovascular diseases in clinic for over four decades. This study intends to explore whether BSKS administration can alleviates hepatic steatosis via improving liver adipon...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Shu-chao, Wang, Shuo, Chen, Mei-ling, Zhang, Jun-ping, Wang, Yuan-yuan, Jia, Hui-yun, Bi, Li-yuan, Wang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393934/
https://www.ncbi.nlm.nih.gov/pubmed/30894877
http://dx.doi.org/10.1155/2019/8986038
_version_ 1783398787829465088
author Pang, Shu-chao
Wang, Shuo
Chen, Mei-ling
Zhang, Jun-ping
Wang, Yuan-yuan
Jia, Hui-yun
Bi, Li-yuan
Wang, Hui
author_facet Pang, Shu-chao
Wang, Shuo
Chen, Mei-ling
Zhang, Jun-ping
Wang, Yuan-yuan
Jia, Hui-yun
Bi, Li-yuan
Wang, Hui
author_sort Pang, Shu-chao
collection PubMed
description BuShenKangShuai tablet (BSKS) is a Chinese herbal compound, which has been used to treat nonalcoholic fatty liver disease and cardiovascular diseases in clinic for over four decades. This study intends to explore whether BSKS administration can alleviates hepatic steatosis via improving liver adiponectin resistance in ApoE(−/−) mice. ApoE(−/−) mice were fed with western-type diet for 6 weeks and then were administrated with BSKS or atorvastatin for 6 weeks by gavage, and then blood and liver were collected for analysis. The results showed that BSKS attenuated hepatic steatosis, decreased blood lipids, and increased the serum level of adiponectin. We also found that adiponectin resistance in the liver was improved by BSKS, while the expression of TLR4 and NF-κB p65 was inhibited, followed by the suppression of proinflammatory mediators of TNF-α. Our data provided evidence that BSKS was able to alleviate hepatic steatosis in vivo. The underlying mechanism of BSKS was focused on improving liver adiponectin resistance, thereby regulating dyslipidemia and inhibiting inflammatory signaling pathway.
format Online
Article
Text
id pubmed-6393934
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-63939342019-03-20 BuShenKangShuai Tablet Alleviates Hepatic Steatosis via Improving Liver Adiponectin Resistance in ApoE(−/−) Mice Pang, Shu-chao Wang, Shuo Chen, Mei-ling Zhang, Jun-ping Wang, Yuan-yuan Jia, Hui-yun Bi, Li-yuan Wang, Hui Evid Based Complement Alternat Med Research Article BuShenKangShuai tablet (BSKS) is a Chinese herbal compound, which has been used to treat nonalcoholic fatty liver disease and cardiovascular diseases in clinic for over four decades. This study intends to explore whether BSKS administration can alleviates hepatic steatosis via improving liver adiponectin resistance in ApoE(−/−) mice. ApoE(−/−) mice were fed with western-type diet for 6 weeks and then were administrated with BSKS or atorvastatin for 6 weeks by gavage, and then blood and liver were collected for analysis. The results showed that BSKS attenuated hepatic steatosis, decreased blood lipids, and increased the serum level of adiponectin. We also found that adiponectin resistance in the liver was improved by BSKS, while the expression of TLR4 and NF-κB p65 was inhibited, followed by the suppression of proinflammatory mediators of TNF-α. Our data provided evidence that BSKS was able to alleviate hepatic steatosis in vivo. The underlying mechanism of BSKS was focused on improving liver adiponectin resistance, thereby regulating dyslipidemia and inhibiting inflammatory signaling pathway. Hindawi 2019-02-13 /pmc/articles/PMC6393934/ /pubmed/30894877 http://dx.doi.org/10.1155/2019/8986038 Text en Copyright © 2019 Shu-chao Pang et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Pang, Shu-chao
Wang, Shuo
Chen, Mei-ling
Zhang, Jun-ping
Wang, Yuan-yuan
Jia, Hui-yun
Bi, Li-yuan
Wang, Hui
BuShenKangShuai Tablet Alleviates Hepatic Steatosis via Improving Liver Adiponectin Resistance in ApoE(−/−) Mice
title BuShenKangShuai Tablet Alleviates Hepatic Steatosis via Improving Liver Adiponectin Resistance in ApoE(−/−) Mice
title_full BuShenKangShuai Tablet Alleviates Hepatic Steatosis via Improving Liver Adiponectin Resistance in ApoE(−/−) Mice
title_fullStr BuShenKangShuai Tablet Alleviates Hepatic Steatosis via Improving Liver Adiponectin Resistance in ApoE(−/−) Mice
title_full_unstemmed BuShenKangShuai Tablet Alleviates Hepatic Steatosis via Improving Liver Adiponectin Resistance in ApoE(−/−) Mice
title_short BuShenKangShuai Tablet Alleviates Hepatic Steatosis via Improving Liver Adiponectin Resistance in ApoE(−/−) Mice
title_sort bushenkangshuai tablet alleviates hepatic steatosis via improving liver adiponectin resistance in apoe(−/−) mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393934/
https://www.ncbi.nlm.nih.gov/pubmed/30894877
http://dx.doi.org/10.1155/2019/8986038
work_keys_str_mv AT pangshuchao bushenkangshuaitabletalleviateshepaticsteatosisviaimprovingliveradiponectinresistanceinapoemice
AT wangshuo bushenkangshuaitabletalleviateshepaticsteatosisviaimprovingliveradiponectinresistanceinapoemice
AT chenmeiling bushenkangshuaitabletalleviateshepaticsteatosisviaimprovingliveradiponectinresistanceinapoemice
AT zhangjunping bushenkangshuaitabletalleviateshepaticsteatosisviaimprovingliveradiponectinresistanceinapoemice
AT wangyuanyuan bushenkangshuaitabletalleviateshepaticsteatosisviaimprovingliveradiponectinresistanceinapoemice
AT jiahuiyun bushenkangshuaitabletalleviateshepaticsteatosisviaimprovingliveradiponectinresistanceinapoemice
AT biliyuan bushenkangshuaitabletalleviateshepaticsteatosisviaimprovingliveradiponectinresistanceinapoemice
AT wanghui bushenkangshuaitabletalleviateshepaticsteatosisviaimprovingliveradiponectinresistanceinapoemice